⚠️ No article content returned.
AstraZeneca PLC (AZN)
- Written by: Madison Wilson
Latest Company News
AstraZeneca reported third-quarter revenue growth of 7% to $16.2 billion, with Core EPS rising 19% to $2.79. The pharmaceutical...
AstraZeneca will invest $2bn in Summit Therapeutics to accelerate the development of ivonescimab and expand its potential use in...
The European Commission has approved AstraZeneca’s Trixeo Aerosphere as a maintenance treatment for patients aged 12 and older whose...
The EMA’s CHMP has recommended Klygefa (gefurulimab) for approval as an add-on treatment for adults with AChR antibody-positive generalised...
The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of...
AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week...
